Major holder exits Innovative Eyewear (LUCY) after 12.1% stake sale

Rhea-AI Filing Summary

Innovative Eyewear Inc. major shareholders Vladimir and Angelica Galkin have fully exited their position. In this Amendment No. 10 to Schedule 13D, they report selling 647,505 shares of common stock, which represented approximately 12.1% of Innovative Eyewear’s outstanding shares, through open market transactions completed effective January 7, 2026.

After these sales, each of the reporting persons beneficially owns 0 shares, or about 0.0% of the company’s common stock, based on 5,350,183 shares outstanding as of November 6, 2025. They state that they no longer believe Innovative Eyewear represents an attractive investment given its business prospects and strategy, and they report no additional plans regarding corporate actions.

Positive

• None.

Negative

• A former major shareholder who held about 12.1% of Innovative Eyewear’s common stock has sold 647,505 shares and reduced ownership to 0%, stating the issuer no longer represents an attractive investment.

Insights

Equity ownership and governance analyst

Former 12.1% holders sold all Innovative Eyewear shares and exited.

The filing shows that Vladimir and Angelica Galkin, previously significant shareholders of Innovative Eyewear Inc., sold 647,505 shares of common stock in open market transactions effective January 7, 2026. These shares represented approximately 12.1% of the company’s outstanding common stock, based on 5,350,183 shares outstanding as of November 6, 2025.

Following these transactions, each reporting person now beneficially owns 0 shares, or about 0.0% of the common stock, meaning they have completely exited their position. They explicitly state that they no longer believe the issuer is an attractive investment in light of its business prospects and strategy, which is a clear negative signal from a former large holder, though it reflects only their own assessment.

The filing also notes that they have no current plans or proposals related to major corporate actions, and no other person has rights to dividends or sale proceeds on the shares they formerly owned. Future company filings may provide additional context on how the shareholder base evolves after the exit of this former 5%-plus owner.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13D

Under the Securities Exchange Act of 1934

(Amendment No. 10)

Innovative Eyewear Inc

(Name of Issuer)

Common Stock, par value $0.00001 per share

(Title of Class of Securities)

45791D109

(CUSIP Number)

Vladimir Galkin
10900 NW 97th Street, #102,
Miami, FL, 33178
(310) 880-6330

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

01/07/2026

(Date of Event Which Requires Filing of This Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

SCHEDULE 13D

CUSIP No. 45791D109

1

Name of reporting person

Galkin Vladimir

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

PF

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 0.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 0.00

11

Aggregate amount beneficially owned by each reporting person

0.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

0 %

14

Type of Reporting Person (See Instructions)

IN

Comment for Type of Reporting Person:

Based on 5,350,183 shares of the Issuer's common stock issued and outstanding as of November 6, 2025, based on information reported by the Issuer in the Quarterly Report on Form 10-Q for the quarter ended September 30, 2025, and filed with the Securities and Exchange Commission (the SEC) on November 13, 2025.

SCHEDULE 13D

CUSIP No. 45791D109

1

Name of reporting person

Galkin Angelica

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

PF

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 0.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 0.00

11

Aggregate amount beneficially owned by each reporting person

0.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

0 %

14

Type of Reporting Person (See Instructions)

IN

Comment for Type of Reporting Person:

Based on 5,350,183 shares of the Issuer's common stock issued and outstanding as of November 6, 2025, based on information reported by the Issuer in the Quarterly Report on Form 10-Q for the quarter ended September 30, 2025, and filed with the Securities and Exchange Commission (the SEC) on November 13, 2025.

SCHEDULE 13D

Item 1.	Security and Issuer
(a)	Title of Class of Securities: Common Stock, par value $0.00001 per share
(b)	Name of Issuer: Innovative Eyewear Inc
(c)	Address of Issuer's Principal Executive Offices: 11900 BISCAYNE BLVD, STE 630, MIAMI, FLORIDA , 33181.
Item 1 Comment: This Amendment No. 10 amends the Schedule 13D filed on September 23, 2024 (the "Original Schedule 13D" and, as amended by Amendment No. 1 to Schedule 13D filed on September 23, 2024, and as amended by Amendment No.2 to Schedule 13D filed on September 23, 2024 , and as amended by Amendment No. 3 filed on September 23, 2024, and as amended by Amendment No. 4 filed on September 24, 2024, and as amended by Amendment No. 5 filed on September 25, 2024, and as amended by Amendment No. 6 filed on October 4, 2024, and as amended by Amendment No. 7 filed on December 12, 2025, and as amended by Amendment No. 8 filed on December 29, 2025, and as amended by Amendment No. 9 filed on January 2, 2026, as amended the "Schedule 13D"). This statement of beneficial ownership on Schedule 13D is jointly filed by each of Vladimir Galkin and Angelica Galkin, husband and wife (collectively, the "Reporting Persons" and individually, a "Reporting Person"), with respect to the shares of the common stock, par value $0.00001 per share (the " Common Stock"), of Innovative Eyewear, Inc., a Florida corporation (the " Issuer"). According to the Issuer, the address of its principal executive office is 1900 Biscayne Blvd., Suite 630, North Miami, Florida 33181. Unless specifically amended hereby, the disclosures set forth in the Original Schedule 13D remain unchanged. Capitalized terms used but not otherwise defined herein have the meanings given to them in the Original Schedule 13D filed on September 23, 2024.
Item 4.	Purpose of Transaction
	Effective January 7, 2026, the Reporting Persons sold 647,505 shares of Common Stock, representing approximately 12.1% of the Issuer's outstanding Common Stock through open market transactions, since their filing of Amendment No. 9 to this Schedule 13D filed on January 2, 2026. The Reporting Persons no longer believe that the Issuer represents an attractive investment based on the Issuer's business prospects and strategy. Other than as set forth above, the Reporting Persons do not have any plans or proposals as of the date of this filing which relate to or would result in any of the actions enumerated in Item 4 of the instructions to Schedule 13D.
Item 5.	Interest in Securities of the Issuer
(a)	As of the date hereof, each of Vladimir Galkin and Angelica Galkin may be deemed to beneficially own 0 shares of Common Stock, representing approximately 0.0% of the issued and outstanding shares of Common Stock of Issuer.
(b)	The foregoing beneficial ownership percentages reported in this Item 5 are based on 5,350,183 shares of the Issuer's Common Stock issued and outstanding as of November 6, 2025, based on information reported by the Issuer in the Quarterly Report on Form 10-Q for the quarter ended September 30, 2025, and filed with the Securities and Exchange Commission (the SEC) on November 13, 2025.
(c)	See Rows 7-10 of the cover page for information regarding the power to vote or direct the vote and the power to dispose or direct the disposition of the shares of Common Stock by each of the Reporting Persons.
(d)	All the transactions involving shares of Common Stock effected during the past sixty (60) days by any of the Reporting Persons, which were all in the open market, are set forth in Schedule A, and are incorporated herein by reference. Except as otherwise noted below, all such transactions were purchases and sales of shares of Common Stock effected in the open market, and the table includes commissions paid in per share prices.
(e)	The Reporting Persons ceased to be the beneficial owner of more than five percent (5%) of the class of securities as of January 7, 2026.
Item 6.	Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer
	No person other than a Reporting Person has the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, Common Stock beneficially owned by the Reporting Persons.
Item 7.	Material to be Filed as Exhibits.
	1. Schedule A 2. Joint Filing Agreement

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Galkin Vladimir

Signature:	Vladimir Galkin
Name/Title:	Individual
Date:	01/07/2026

Galkin Angelica

Signature:	Angelica Galkin
Name/Title:	Individual
Date:	01/07/2026

FAQ

What does this Schedule 13D/A filing report for Innovative Eyewear (LUCY)?

It reports that Vladimir and Angelica Galkin, who jointly filed as reporting persons, have sold all of their Innovative Eyewear common shares and now beneficially own 0 shares, or about 0.0% of the company’s outstanding stock.

How many Innovative Eyewear shares did the Galkins sell in this amendment?

The filing states that, effective January 7, 2026, the reporting persons sold 647,505 shares of Innovative Eyewear common stock in open market transactions, which represented approximately 12.1% of the issuer’s outstanding common stock.

What percentage of Innovative Eyewear did the Galkins own after these transactions?

As of the date of the filing, each of Vladimir and Angelica Galkin beneficially owns 0 shares of Innovative Eyewear common stock, representing approximately 0.0% of the issued and outstanding shares.

On what share count is the 12.1% and 0.0% ownership of Innovative Eyewear based?

The reported ownership percentages are based on 5,350,183 shares of Innovative Eyewear common stock issued and outstanding as of November 6, 2025, as disclosed in the company’s Form 10-Q for the quarter ended September 30, 2025.

Why did the Galkins decide to exit their Innovative Eyewear investment?

The reporting persons state that they no longer believe the issuer represents an attractive investment based on Innovative Eyewear’s business prospects and strategy, and therefore sold their shares.

Do the reporting persons have any plans to influence Innovative Eyewear after this sale?

According to the filing, other than the described sale of 647,505 shares, the reporting persons do not have plans or proposals that would result in actions listed under Item 4, such as mergers, reorganizations, or other major corporate changes.